<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The first formal classification of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> is credited to William Dameshek, who in 1951 described the concept of "<z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>)" by grouping together <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET), and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF) </plain></SENT>
<SENT sid="1" pm="."><plain>The 2001 World Health Organization (WHO) classification of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> included these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPDs</z:e> under the broader category of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>), which also included <z:hpo ids='HP_0011010'>chronic</z:hpo> neutrophilic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> eosinophilic <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:e sem="disease" ids="C1540912" disease_type="Neoplastic Process" abbrv="">hypereosinophilic syndrome</z:e> (CEL/HES), and "<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>, unclassifiable." The revised 2008 WHO classification system featured the following changes: 1) the term "<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>" was replaced by "myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (MPN)," 2) <z:e sem="disease" ids="C0024899" disease_type="Disease or Syndrome" abbrv="">mast cell disease</z:e> was formally included under the category of MPN, and 3) the subcategory of CEL/HES was reorganized into "CEL not otherwise specified (CEL-NOS)" and "myeloid and lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> with <z:hpo ids='HP_0001880'>eosinophilia</z:hpo> and abnormalities of PDGFRA, PDGFRB, and FGFR1"; CEL-NOS remained a subcategory of "MPN," whereas the latter <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were now assigned a new category of their own </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, diagnostic criteria for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, ET, and PMF were revised by incorporating recently described molecular markers (eg, JAK2 and MPL mutations) as well as underscoring the role of histology in differentiating reactive from clonal myeloproliferations </plain></SENT>
<SENT sid="3" pm="."><plain>As a result, red cell mass measurement is no longer necessary for the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, and ET can now be diagnosed at a lower platelet count threshold </plain></SENT>
<SENT sid="4" pm="."><plain>The revised WHO document continues to promote the recognition of histologic categories as a necessary first step toward the genetic characterization of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
</text></document>